Clinical Trial Update: A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases

View source ↗

Summary

Clinical trial update for furmonertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis; the study is currently active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Qiming Wang | Conditions: Lung Cancer (NSCLC), Leptomeningeal Cancer | Status: ACTIVE_NOT_RECRUITING